CD160 Antibody (BY55)
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-21435
Clone BY55 was used by HLDA to establish CD designation.
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow Cytometry, Immunoprecipitation
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgM Clone # BY55
Concentration
0.1 mg/ml
Product Summary for CD160 Antibody (BY55)
Immunogen
Human NK cell line YT2C2
Reactivity Notes
Reacts with Human.
Specificity
NBP1-21435 recognizes human CD160, a 27kD cell surface glycoprotein that was initially identified by clone BY55. The expression of CD160 is restricted to circulating NK cells, lymphocytes expressing T-cell receptor (TCR) gamma/delta and a small population of TCR alpha/beta positive T cells. In tissues, CD160 is expressed by intestinal intraepithelial lymphocytes.
Clonality
Monoclonal
Host
Mouse
Isotype
IgM
Scientific Data Images for CD160 Antibody (BY55)
Flow Cytometry: CD160 Antibody (BY55) [NBP1-21435]
Flow Cytometry: CD160 Antibody (BY55) [NBP1-21435] - Staining of human peripheral blood lymphocytes with Mouse anti Human CD160Flow Cytometry: CD160 Antibody (BY55) [NBP1-21435]
Flow Cytometry: CD160 Antibody (BY55) [NBP1-21435] - Staining of human peripheral blood lymphocytes with Mouse anti Human CD160:Azide FreeApplications for CD160 Antibody (BY55)
Application
Recommended Usage
Flow Cytometry
1:10-1:50
Immunoprecipitation
1:10-1:500
Application Notes
In Flow use 10ul of the suggested working dilution to label 106 cells in 100ul. Method sheets are available on request
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
IgM purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
0.1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CD160
Identified ligands for CD160 include MHC class I proteins and herpes virus entry mediators (HVEM), each of which has a different effect on NK or T cells (1,3-5). CD160 binds to MHC class I proteins with weaker affinity, but the interaction causes NK cell cytotoxic function and cytokine production (1,3). CD160 engagement of MHC class I proteins and/or HVEM within NK cells promotes ERK1/2 and AKT activation and production of interferon gamma (IFNgamma) (5). Conversely, CD160 binding of HVEM in CD4+ T cells induces inhibitory signaling, signifying both a stimulatory and inhibitory role for CD160 as well as cell-specific context (4,5). Additionally, CD160 plays a role in diseases including certain types of cancer, such as thyroid cancer and colon cancer, viral infections, and autoimmune diseases (3,5). CD160 expression levels on CD8+ T cells have been shown to be elevated in chronic viral infections such as human immunodeficiency virus (HIV) and Epstein Barr virus (EBV) (3). In addition, when CD160 is co-expressed with the programmed cell death protein 1 (PD-1) receptor, T cell exhaustion occurs due to persistent stimulation, leading to inhibited immune response and ability to combat infection (3). CD160 may be a promising therapeutic target in cancer as murine studies have demonstrated that blocking the CD160-HVEM pathway causes a regression of neoplastic tumors in a thyroid cancer model (3-5).
References
1. Le Bouteiller P, Tabiasco J, Polgar B, et al. CD160: a unique activating NK cell receptor. Immunol Lett. 2011;138(2):93-96. https://doi.org/10.1016/j.imlet.2011.02.003
2. Uniprotkb (O95971)
3. Piotrowska M, Spodzieja M, Kuncewicz K, Rodziewicz-Motowidlo S, Orlikowska M. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem. 2021;224:113694. https://doi.org/10.1016/j.ejmech.2021.113694
4. Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev. 2009;229(1):244-258. https://doi.org/10.1111/j.1600-065X.2009.00783.x
5. Sedy JR, Ramezani-Rad P. HVEM network signaling in cancer. Adv Cancer Res. 2019;142:145-186. https://doi.org/10.1016/bs.acr.2019.01.004
Additional CD160 Products
Product Documents for CD160 Antibody (BY55)
Product Specific Notices for CD160 Antibody (BY55)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...